Orca Bio Overview
Pro stress-test →Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer and autoimmune diseases. The company's manufacturing platform sorts donor blood with single-cell precision and a high level of purity and speed, enabling creation of proprietary, optimal therapeutic mixtures of immune and stem cells. The company is advancing toward regulatory approval with a critical inflection point in 2026.
Strategic Profile
Pro stress-test →Orca Bio has built a centralized 100,000 square foot manufacturing facility to ensure consistent and reliable delivery of high-precision cell therapies at scale, with donor to patient vein-to-vein turnaround times of 72 hours or less. The company completed a Series F financing round in December 2025 led by Lightspeed Venture Partners, raising $250M in new equity capital from its two most recent financing rounds, along with a 2025 amendment to its Silicon Valley Bank credit facility providing up to $100M in additional liquidity.
Competitive Landscape
Pro stress-test →Orca Bio operates in the allogeneic cell therapy space competing against other cell therapy developers. Key competitors include companies developing CAR-T therapies, other allogeneic cell therapy platforms, and traditional hematopoietic stem cell transplantation alternatives. The company's differentiation centers on proprietary single-cell precision manufacturing and regulatory T-cell composition design reducing toxicity while maintaining efficacy.
Industry Context
Orca Bio operates in Cell Therapy / Regenerative Medicine.
Key facts
Founded: 2016 · Headquarters: Menlo Park, US · Employees: 51-200